Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)

Inclusion Criteria: * Has a primary diagnosis of painful diabetic neuropathy (PDN) for at least 6 months. * Is able to understand \& use an electronic diary to complete daily questionnaires. * If female of reproductive potential, agrees to use acceptable contraception from Screening through to at least 2 weeks after last dose of study drug. * Is on a stable dose of antihyperglycemic treatment for at least 1 month, with hemoglobin A1C level of no more than 11%. * If taking an allowable around-the-clock medication for chronic pain, has been on a stable dose for at least 1 month \& agrees to stay on same dose during the study. * Agrees to not start therapy with opioids, pregabalin, gabapentin, duloxetine or any other medications used to treat neuropathic pain during the study. * Has a regular bedtime of before 1 AM (01:00). * Agrees to limit alcohol consumption to no more than 3 drinks a day, with no drinks within 3 hours before bedtime. One drink is defined as: 1) 12 ounces of beer; 2) 4 ounces of wine; or 3) 1 ounce of liquor (80 proof or 40% alcohol). * Agrees to limit caffeine consumption to no more than 5 standard 6-oz. cups of caffeinated beverages or no more than 600 mg caffeine a day, with no caffeinated beverages after 4 PM (16:00). * Agrees to maintain a relatively consistent level of activity throughout the study. Exclusion Criteria: * Is pregnant or breastfeeding, or expects to become pregnant during the study. * Expects to donate eggs or sperm during the study or…